FDA Approves Nedosiran Injection for Children and Adults Wit

Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.

Related Keywords

United States , Kim Hollander , Blandine Lacroix , P Novo Nordisk , Novo Nordisk Inc , Oxalosis Hyperoxaluria Foundation , Novo Nordisk , Hyperoxaluria Foundation , Rare Disease , Rivfloza , Nedosiran , Primary Hyperoxaluria , Ph1 ,